Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial - Report - MDSpire
Advertisement
Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Osteoporosis Treatment Post-Parathyroidectomy in Primary Hyperparathyroidism
Overview
This randomized, double-blind, placebo-controlled study evaluated the efficacy of strontium ranelate (SR) on bone mineral density (BMD) in osteopenic and osteoporotic patients following successful parathyroidectomy (PTX) for primary hyperparathyroidism (pHPT). SR treatment significantly improved BMD at the lumbar spine and other skeletal sites compared to placebo over one year. The study also explored changes in bone metabolism markers, including sclerostin and Dickkopf-1, to understand anabolic pathways post-PTX.
Background
Primary hyperparathyroidism increases bone turnover, leading to decreased BMD and elevated fracture risk, particularly vertebral fractures. Parathyroidectomy is the definitive treatment but often results in only modest BMD improvements, leaving patients at risk for fractures for years post-surgery. Anti-osteoporotic medications that stimulate bone formation, such as strontium ranelate, may enhance BMD recovery after PTX. The Wnt signaling pathway, involving sclerostin and Dickkopf-1, represents a novel target for anabolic bone therapies but has not been studied in this context.
Data Highlights
Parameter
Placebo Group (PG)
Strontium Group (SG)
Difference
Lumbar Spine BMD Change (%)
Minor or no significant increase
Significant increase (up to 4%)
SR superior to placebo
Femoral Neck BMD Change (%)
Minimal change
Significant improvement
SR superior
Radius BMD Change (%)
No significant change
Improvement at 1/3, MID, UD radius
SR superior
Bone Turnover Markers
Variable
Improved markers indicating increased bone formation
SR effect observed
Key Findings
Parathyroidectomy alone results in modest BMD increases, insufficient for many osteoporotic patients.
Strontium ranelate treatment post-PTX significantly increases BMD at lumbar spine, femoral neck, and radius compared to placebo.
SR exerts dual action by stimulating osteoblasts and inhibiting osteoclasts, enhancing bone formation and reducing resorption.
Bone turnover markers improved with SR, indicating anabolic effects on bone metabolism after PTX.
Wnt pathway markers sclerostin and Dickkopf-1 were analyzed, suggesting potential future therapeutic targets for enhancing bone formation post-PTX.
Clinical Implications
For patients with pHPT and low BMD undergoing PTX, adjunctive treatment with anabolic osteoporosis medications like strontium ranelate may accelerate and augment BMD recovery, potentially reducing fracture risk. Monitoring bone turnover markers and exploring Wnt pathway modulators could refine post-surgical osteoporosis management. Clinicians should consider patient-specific risk factors and contraindications when initiating such therapies.
Conclusion
This study demonstrates that anabolic osteoporosis treatment with strontium ranelate after successful parathyroidectomy significantly improves bone mineral density and bone metabolism markers in patients with low preoperative BMD. These findings support the use of targeted osteoporosis therapies to optimize skeletal recovery and reduce fracture risk post-PTX.
References
Medical University of Vienna et al. 2024 -- Efficacy of Osteoporosis Treatment Following Successful Parathyroidectomy for Primary Hyperparathyroidism
by Martin B. Niederle, Ursula Foeger-Samwald, Philipp Riss, Andreas Selberherr, Christian Scheuba, Peter Pietschmann, Bruno Niederle, Katharina Kerschan-Schindl
These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.
